113579-02-5

Basic information

• Product Name: haloperidol-succinylglycyliodotyrosine
• Synonyms: haloperidol-succinylglycyliodotyrosine
• CAS NO: 113579-02-5
• Molecular Formula: C36H38ClFIN3O8
• Molecular Weight: 821.0490932
• Mol File: 113579-02-5.mol
• Article Data: 0

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.57g/cm³
• Refractive Index: 1.655
• CAS DataBase Reference: haloperidol-succinylglycyliodotyrosine(CAS DataBase Reference)
• NIST Chemistry Reference: haloperidol-succinylglycyliodotyrosine(113579-02-5)
• EPA Substance Registry System: haloperidol-succinylglycyliodotyrosine(113579-02-5)

Safety Data

• Hazardous Substances Data: 113579-02-5(Hazardous Substances Data)

Usage

Description

Haloperidol-succinylglycyliodotyrosine is a chemical compound synthesized by esterifying haloperidol, an antipsychotic medication, with succinylglycine and iodotyrosine. haloperidol-succinylglycyliodotyrosine is specifically designed for use in medical imaging, offering insights into the brain's dopamine receptor density, which is integral to understanding various neurological functions and disorders.

Uses

Used in Medical Imaging:
Haloperidol-succinylglycyliodotyrosine serves as a radiotracer in positron emission tomography (PET) studies. It is utilized for visualizing and quantifying the density of dopamine receptors in the brain. haloperidol-succinylglycyliodotyrosine is instrumental in investigating the role of dopamine receptors in neurological functions and their potential abnormalities linked to psychiatric conditions.
Used in Psychiatric Disorder Research:
In the field of psychiatric research, haloperidol-succinylglycyliodotyrosine is applied to study the mechanisms underlying disorders such as schizophrenia and bipolar disorder. haloperidol-succinylglycyliodotyrosine aids in identifying how variations in dopamine receptor density may contribute to these conditions, thereby facilitating the development of more precise and effective treatment strategies.
Used in Drug Development:
Haloperidol-succinylglycyliodotyrosine also plays a role in the pharmaceutical industry, particularly in the development of new drugs targeting dopamine receptors. By providing a means to assess receptor density and distribution, this compound can help in evaluating the efficacy of potential treatments and their impact on the brain's dopamine system.

InChI:InChI=1/C36H38ClFIN3O8/c37-26-8-6-25(7-9-26)36(15-18-42(19-16-36)17-1-2-30(43)24-4-10-27(38)11-5-24)50-34(47)14-13-32(45)40-22-33(46)41-29(35(48)49)21-23-3-12-31(44)28(39)20-23/h3-12,20,29,44H,1-2,13-19,21-22H2,(H,40,45)(H,41,46)(H,48,49)/t29-/m0/s1/i39-2